• SENSEX
    NIFTY 50
Healthcare

Zydus Cadila inks non-exclusive licensing pact with Gilead Sciences to manufacture and market Remdesivir

Updated : June 13, 2020 08:59 AM IST

As part of the non-exclusive agreement, Zydus will receive the manufacturing know-how from Gilead Sciences Inc.
Zydus will leverage its ability to scale up production to reach patients across India and across the 127 countries in Gilead’s Global Patient Solution region.
Zydus Cadila inks non-exclusive licensing pact with Gilead Sciences to manufacture and market Remdesivir

You May Also Like

Live TV
Advertisement